Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. - Wikidata - awgldk - TriplyDB

Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.

Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.

http://www.wikidata.org/entity/Q34609688

about

Safety of intravenous iron formulations: facts and folklore Considerations and challenges in defining optimal iron utilization in hemodialysis On the relative safety of parenteral iron formulations Safety of intravenous iron in hemodialysis patients.Ferumoxytol for the treatment of iron deficiency.Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.Intravenous iron replacement with sodium ferric gluconate complex in sucrose for iron deficiency anemia in adults.The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee.Iron, anaemia, and inflammatory bowel diseases.Effect of Intravenous Iron Supplementation on Acute Mountain Sickness: A Preliminary Randomized Controlled Study.Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.Understanding renal posttransplantation anemia in the pediatric population.Iron deficiency anaemia in pregnancy and postpartum: pathophysiology and effect of oral versus intravenous iron therapy.Benefits and risks of iron therapy for chronic anaemias.Intravenous iron therapy: well-tolerated, yet not harmless.Haemodialysis-associated anaphylactic and anaphylactoid reactions.Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex.Ferumoxytol for treating iron deficiency anemia in CKD Short-term benefits and risks of intravenous iron: a systematic review and meta-analysis.Safety issues with intravenous iron products in the management of anemia in chronic kidney disease A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.How we diagnose and treat iron deficiency anemia.Single-dose intravenous iron for iron deficiency: a new paradigm.The available intravenous iron formulations: History, efficacy, and toxicology.Treatment of renal anemia: Erythropoiesis stimulating agents and beyond.The rise and rise of randomized clinical evidence in Sub-Saharan Africa.Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects.Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study.Update on adverse drug events associated with parenteral iron.Nebivolol reduces experimentally induced warm renal ischemia reperfusion injury in rats.The comparative safety of various intravenous iron preparations in chronic kidney disease patients.Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.Acute hypersensitivity reaction to ferric gluconate in a premedicated patient.Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: In Vitro Cellular Uptake.Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease.

P2860

Q26853397-8B4308B0-BC56-45BC-95DA-486F9B28D027 Q28088564-A25C280E-B27A-4945-BA69-7366BE4E7BC0 Q28262418-ADC52DF3-E926-4DCC-9007-05FE9B7AC2BB Q30234981-C0CA232F-EB40-47EA-AA21-A2857C544964 Q30454001-B22AD3AB-986F-4EA1-B441-059CFEC231D2 Q33279821-4A7E4E01-FE2B-4723-8CA9-78289F16801E Q33738876-065AE180-950A-4F37-B8C7-44A7411934CE Q35128983-5654FE63-C38B-4F17-8029-901A0FA325CF Q35596692-A5A1437C-7D81-4A1C-87CD-568EA7173383 Q35891670-D91C75BD-B69E-4896-AEAF-700B0B0CDF27 Q35931905-99B8EEFB-5C49-420A-BCCF-2DCA35C71776 Q35976513-F4A69F79-CD1B-4557-B834-D151618576C6 Q35996211-ADB9D5F6-BE23-4239-AF34-655BBA2B15E3 Q36076079-4F05717F-7DE4-483F-886F-5185051B8E01 Q36310898-5D4D95FB-63C1-44EE-91BD-41F010132A9F Q36310902-87169C46-581E-4EC8-A78B-361F1A248FD0 Q36366935-E8ACF0E0-BB1C-4A47-87BA-93ADADB98A7F Q36577123-301D3E0F-41E9-4B2B-A9B1-7D7B1A71053A Q36796801-0C13ED6C-7625-4C5B-9D34-6E8780C06826 Q36946004-59A82E21-1407-4298-8B93-994B411151F7 Q37161960-AFAD1734-ABC8-4C36-9DF1-6D34625EC55A Q37838114-F36E0D3A-F17A-4755-B6DB-C63267001D32 Q38593099-8745C4A9-A656-4176-9441-F6D24E41CF34 Q39027699-38E51EB1-F484-4FBA-80B2-DCEE55385B30 Q39216462-1F226F32-B411-49F2-A60A-2BC014FAB3C4 Q41387413-BA8991AD-7F6C-4939-A43D-CDC4F190A619 Q42350634-F94220DA-FCAD-406A-AB61-4075769A9140 Q44910309-83F5049F-B5A4-4AC7-AB1F-B922726420B0 Q45136882-C43692AE-682D-4739-8031-54A59D938423 Q46212164-4506836E-CC54-44E6-9F0B-6FB6FF9EC451 Q46313772-D1DEB43A-B323-428E-907A-2EBBDE2F7CFA Q46459696-2897CCE9-E84B-48B2-8D0E-A3EFF4D1B445 Q46796463-DB2092CA-8C41-4E31-822A-C8EA282DBB51 Q46803781-6F64950A-1E8F-433E-BA40-6337C054E003 Q47103693-0073D043-CD44-49C2-A0BD-9D6B566529C9 Q47111895-636C1812-83A9-4185-9887-1D17BB0BA368

P2860

Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.

http://www.wikidata.org/entity/Q34609688

description

2002 nî lūn-bûn

@nan

2002 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Sodium ferric gluconate comple ...... d to placebo and iron dextran.

@ast

Sodium ferric gluconate comple ...... d to placebo and iron dextran.

@en

Sodium ferric gluconate comple ...... d to placebo and iron dextran.

@nl

type

label

Sodium ferric gluconate comple ...... d to placebo and iron dextran.

@ast

Sodium ferric gluconate comple ...... d to placebo and iron dextran.

@en

Sodium ferric gluconate comple ...... d to placebo and iron dextran.

@nl

prefLabel

Sodium ferric gluconate comple ...... d to placebo and iron dextran.

@ast

Sodium ferric gluconate comple ...... d to placebo and iron dextran.

@en

Sodium ferric gluconate comple ...... d to placebo and iron dextran.

@nl

P1433

Q34609688-99BD51BF-ACCB-4450-A0BC-50BEE1CF6226

P1476

Q34609688-9B21292F-B1BF-49AD-854C-B70657019C80

P2093

Q34609688-1CA63930-C93B-4F33-AF6F-4A3F78CEE896

Q34609688-2FD1552C-065B-4C52-9FC0-409E2632F398

Q34609688-55C79452-1743-4756-9678-990E4B317185

Q34609688-5C5816D2-CF96-4B5B-B078-7FB8BA02EBD8

Q34609688-5D33C79F-181D-492A-BDD6-9FE55244D180

Q34609688-91B23E8B-DFE0-456E-82B4-535EE7DA9107

Q34609688-9C68A82C-1565-4FFB-AC46-43F96D0526BD

Q34609688-9D517511-E071-4EFB-B8B6-89E4534000F7

Q34609688-A1A5D7A1-7084-425E-BDAC-83B6F96074AA

Q34609688-E1F07CDB-B58B-44DF-BD30-5198754EA47D

P2888

Q34609688-BD2F5178-DAE8-472D-B2C8-D52591C55B56

P304

Q34609688-396C7392-E173-48C1-9AAC-BFDB477182B4

P31

Q34609688-38A8BC4D-F168-45D7-9C63-2CD9BBA0F5C6

P356

Q34609688-31DE72D7-C6C5-4B96-A1F4-CFE5FF6539E3

P407

Q34609688-7C953AD8-F15A-4CEB-940C-5765315BFAC7

P433

Q34609688-A1DB0B5A-DA34-4C10-AF76-89EB90E8C96D

P478

Q34609688-04C4C214-985A-471B-817A-6BE67B9BEF31

P577

Q34609688-A8E9435D-6B80-4BC8-847F-72278A956A99

P5875

Q34609688-2FACC9F7-4FB1-4A01-8AB1-5579A3EACF66

P6179

Q34609688-E2D7C270-BFD8-4123-BF68-DD00698A8FF7

P698

Q34609688-C31C67BF-CBC2-4646-9E0C-2A903B458BB2

P921

Q34609688-0C6F4CBA-E52A-4D93-BDA4-A4226B70A711

P356

J.1523-1755.2002.00314.X

P1433

Kidney International

P1476

Sodium ferric gluconate comple ...... d to placebo and iron dextran.

@en

P2093

Allen R Nissenson

http://www.w3.org/2001/XMLSchema#string

Beckie Michael

http://www.w3.org/2001/XMLSchema#string

Daniel W Coyne

http://www.w3.org/2001/XMLSchema#string

David G Warnock

http://www.w3.org/2001/XMLSchema#string

Ferrlecit Publication Committee

http://www.w3.org/2001/XMLSchema#string

J Richard Trout

http://www.w3.org/2001/XMLSchema#string

Joseph W Eschbach

http://www.w3.org/2001/XMLSchema#string

Jur Strobos

http://www.w3.org/2001/XMLSchema#string

Rajiv Agarwal

http://www.w3.org/2001/XMLSchema#string

Robert Lynn

http://www.w3.org/2001/XMLSchema#string

P2888

j.1523-1755.2002.00314.x

P304

1830-1839

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1523-1755.2002.00314.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2002-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11401073

http://www.w3.org/2001/XMLSchema#string

P6179

1017968576

http://www.w3.org/2001/XMLSchema#string

P698

11967034

http://www.w3.org/2001/XMLSchema#string

P921